AR104771A1 - Inhalador de polvo seco - Google Patents
Inhalador de polvo secoInfo
- Publication number
- AR104771A1 AR104771A1 ARP160100136A ARP160100136A AR104771A1 AR 104771 A1 AR104771 A1 AR 104771A1 AR P160100136 A ARP160100136 A AR P160100136A AR P160100136 A ARP160100136 A AR P160100136A AR 104771 A1 AR104771 A1 AR 104771A1
- Authority
- AR
- Argentina
- Prior art keywords
- dry powder
- dose
- fluticasone propionate
- powder inhaler
- patient
- Prior art date
Links
- 229960000289 fluticasone propionate Drugs 0.000 abstract 4
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 229960005018 salmeterol xinafoate Drugs 0.000 abstract 2
- 229940112141 dry powder inhaler Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105479P | 2015-01-20 | 2015-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104771A1 true AR104771A1 (es) | 2017-08-16 |
Family
ID=55443303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100136A AR104771A1 (es) | 2015-01-20 | 2016-01-20 | Inhalador de polvo seco |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9415008B2 (enExample) |
| EP (1) | EP3247331A1 (enExample) |
| JP (1) | JP2018503687A (enExample) |
| KR (1) | KR20170103975A (enExample) |
| CN (1) | CN107530357A (enExample) |
| AR (1) | AR104771A1 (enExample) |
| AU (2) | AU2016209363B2 (enExample) |
| BR (1) | BR112017015353A2 (enExample) |
| CA (1) | CA2974125A1 (enExample) |
| CL (1) | CL2017001859A1 (enExample) |
| CO (1) | CO2017008395A2 (enExample) |
| EA (1) | EA201791632A1 (enExample) |
| HK (1) | HK1245125A1 (enExample) |
| IL (1) | IL253499A0 (enExample) |
| MA (1) | MA41378A (enExample) |
| MX (2) | MX383344B (enExample) |
| PE (1) | PE20171258A1 (enExample) |
| TW (1) | TW201628607A (enExample) |
| WO (1) | WO2016118589A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160243320A1 (en) * | 2013-10-07 | 2016-08-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Dry powder inhaler |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| ES2884802T3 (es) * | 2016-11-18 | 2021-12-13 | Norton Waterford Ltd | Dispositivo de administración de fármacos con componentes electrónicos |
| CN110201278B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
| CN110201280B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药装置的吸嘴和吸入给药装置 |
| CN110201281B (zh) * | 2018-02-28 | 2021-08-06 | 张江 | 吸入给药装置和吸入给药组合结构 |
| CN110064110A (zh) * | 2019-05-29 | 2019-07-30 | 上海理工大学 | 一种容积旋钮式干粉储存吸入装置 |
| GB2585206B (en) * | 2019-07-01 | 2021-08-11 | Merxin Ltd | Portable inhaler |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| AR028747A1 (es) | 2000-06-23 | 2003-05-21 | Norton Health Care Ltd | Desaglomerador para inhalador de polvo seco accionado por la respiracion, un inhalador de polvo seco y un metodo de desaglomeracion de polvo seco. |
| TWI224514B (en) * | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | Dose metering system for medicament inhaler |
| AR030516A1 (es) * | 2000-08-31 | 2003-08-20 | Glaxo Group Ltd | Uso de una combinacion de salmeterol y fluticasona |
| DK1337240T4 (en) * | 2000-11-30 | 2015-01-05 | Vectura Ltd | A process for the preparation of particles for use in a pharmaceutical composition |
| GB0124523D0 (en) | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
| CN1694689A (zh) | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| TWI792140B (zh) * | 2009-05-29 | 2023-02-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統 |
| CN102573886A (zh) * | 2009-09-17 | 2012-07-11 | 相互制药公司 | 用抗病毒剂治疗哮喘的方法 |
| GB0919465D0 (en) * | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
| PL2436414T3 (pl) * | 2010-05-18 | 2015-10-30 | Ivax Pharmaceuticals Ireland | Licznik dawek do inhalatorów i inhalator |
| WO2011145109A1 (en) | 2010-05-20 | 2011-11-24 | Sun Pharma Advanced Research Company Ltd., | Dry powder inhalation composition |
| KR20130140358A (ko) * | 2012-06-14 | 2013-12-24 | 한미약품 주식회사 | 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 |
| AU2014261539A1 (en) * | 2013-04-29 | 2015-12-10 | Sanofi Sa | Inhalable pharmaceutical compositions and the inhaler devices containing them |
| CN105358520B (zh) * | 2013-05-03 | 2017-05-03 | 陶氏环球技术有限责任公司 | 平衡限制反应的方法 |
| US20160243320A1 (en) | 2013-10-07 | 2016-08-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Dry powder inhaler |
| JP6653324B2 (ja) * | 2014-10-16 | 2020-02-26 | テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド | 乾燥粉末製剤 |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
-
2016
- 2016-01-19 MA MA041378A patent/MA41378A/fr unknown
- 2016-01-20 EP EP16706919.4A patent/EP3247331A1/en not_active Withdrawn
- 2016-01-20 MX MX2017009122A patent/MX383344B/es unknown
- 2016-01-20 TW TW105101637A patent/TW201628607A/zh unknown
- 2016-01-20 JP JP2017556791A patent/JP2018503687A/ja active Pending
- 2016-01-20 US US15/001,853 patent/US9415008B2/en active Active
- 2016-01-20 HK HK18104726.3A patent/HK1245125A1/zh unknown
- 2016-01-20 WO PCT/US2016/014072 patent/WO2016118589A1/en not_active Ceased
- 2016-01-20 CN CN201680011413.7A patent/CN107530357A/zh active Pending
- 2016-01-20 US US15/544,900 patent/US20180015035A1/en not_active Abandoned
- 2016-01-20 KR KR1020177023075A patent/KR20170103975A/ko not_active Ceased
- 2016-01-20 AU AU2016209363A patent/AU2016209363B2/en active Active
- 2016-01-20 CA CA2974125A patent/CA2974125A1/en not_active Abandoned
- 2016-01-20 PE PE2017001234A patent/PE20171258A1/es unknown
- 2016-01-20 BR BR112017015353A patent/BR112017015353A2/pt not_active Application Discontinuation
- 2016-01-20 EA EA201791632A patent/EA201791632A1/ru unknown
- 2016-01-20 AR ARP160100136A patent/AR104771A1/es active IP Right Grant
-
2017
- 2017-07-12 MX MX2021006751A patent/MX2021006751A/es unknown
- 2017-07-16 IL IL253499A patent/IL253499A0/en unknown
- 2017-07-18 CL CL2017001859A patent/CL2017001859A1/es unknown
- 2017-08-17 CO CONC2017/0008395A patent/CO2017008395A2/es unknown
-
2021
- 2021-05-04 AU AU2021202784A patent/AU2021202784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1245125A1 (zh) | 2018-08-24 |
| US9415008B2 (en) | 2016-08-16 |
| KR20170103975A (ko) | 2017-09-13 |
| AU2016209363B2 (en) | 2021-02-04 |
| MX2017009122A (es) | 2017-10-12 |
| BR112017015353A2 (pt) | 2018-01-16 |
| US20160206559A1 (en) | 2016-07-21 |
| CA2974125A1 (en) | 2016-07-28 |
| PE20171258A1 (es) | 2017-08-28 |
| JP2018503687A (ja) | 2018-02-08 |
| WO2016118589A1 (en) | 2016-07-28 |
| EP3247331A1 (en) | 2017-11-29 |
| CN107530357A (zh) | 2018-01-02 |
| EA201791632A1 (ru) | 2017-12-29 |
| CL2017001859A1 (es) | 2018-04-06 |
| MX2021006751A (es) | 2021-07-15 |
| CO2017008395A2 (es) | 2018-01-05 |
| US20180015035A1 (en) | 2018-01-18 |
| AU2021202784A1 (en) | 2021-05-27 |
| MX383344B (es) | 2025-03-13 |
| IL253499A0 (en) | 2017-09-28 |
| MA41378A (fr) | 2017-11-28 |
| TW201628607A (zh) | 2016-08-16 |
| AU2016209363A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004316A (es) | Inhalador de polvo seco. | |
| AR104771A1 (es) | Inhalador de polvo seco | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| MX2022009231A (es) | Inhalador de polvo seco y metodo de uso. | |
| BR112021022503A2 (pt) | Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo | |
| BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MX2015016418A (es) | Dihidroetorfina para proporcionar el alivio del dolor y la anestesia. | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| AR102903A1 (es) | Inhalador de polvo seco | |
| AR094287A1 (es) | Metodos y composiciones para administracion de oxibutinina | |
| TH173838A (th) | เครื่องพ่นละอองยาผงแห้ง | |
| Smith | Carbamazepine accelerates liver regeneration in mice after acute injury | |
| UA105586U (uk) | Спосіб лікування печінкової енцефалопатії | |
| AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente | |
| MD596Y (en) | Method for treating the chronic viral hepatitis C | |
| DHS | Cyclobenzaprine/lamotrigine interaction | |
| BR112019005168A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |